Induced hypertension treatment to improve cerebral ischemic injury after transient forebrain ischemia.
The effect of induced hypertension treatment on cerebral ischemia is still controversial. We investigated the preferred blood pressure manipulation level and pressor agent required to reduce cerebral ischemic injury following transient forebrain ischemia induced by bilateral occlusion of the common carotid arteries in anesthetized gerbils. Following 60-min cerebral ischemia, we evaluated the preferred blood pressure manipulation level and pressor agent required to treat cerebral ischemic injury after reperfusion by examining the effects of different levels of mean arterial blood pressure (MABP), increased with phenylephrine or angiotensin II or decreased by blood withdrawal, on cerebral blood flow (CBF), survival ratio, cerebral edema, and brain energy metabolism following transient forebrain ischemia in gerbils. Mild phenylephrine-induced hypertension treatment (21+/-4 mmHg) during post-cerebral ischemia-reperfusion improved the survival ratio and reduced cerebral edema, which was also associated with an increase in local CBF and a recovery of brain energy metabolism. However, intense phenylephrine-induced hypertension, angiotensin II-induced hypertension, or hypotension worsen the survival rate and produced extra cerebral edema, that were also associated with deterioration of brain energy metabolism. These results demonstrate that a mild induced hypertension with phenylephrine (21+/-4 mmHg above the baseline level) results in reduction of the cerebral edema and improves the survival ratio and brain energy metabolism. Furthermore, angiotensin II may have neurotoxic effect to use as the pressor agent for induced hypertension after cerebral ischemia.
Hosomi
N
N
Second Department of Internal Medicine, Kagawa Medical University School of Medicine, Kagawa 761-0793, Japan. nhosomi@scripps.edu
Mizushige
K
K
Kitadai
M
M
Ohyama
H
H
Ichihara
S I
SI
Takahashi
T
T
Matsuo
H
H
D000255:Adenosine Triphosphate / Q000378:metabolism; D000704:Analysis of Variance; D000804:Angiotensin II / Q000627:therapeutic use; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001929:Brain Edema / Q000188:drug therapy / Q000209:etiology; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D005849:Gerbillinae; D006973:Hypertension / Q000139:chemically induced*; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D010656:Phenylephrine / Q000627:therapeutic use; D010725:Phosphocreatine / Q000031:analogs & derivatives / Q000378:metabolism; D016548:Prosencephalon / Q000098:blood supply / Q000187:drug effects*; D015427:Reperfusion Injury / Q000150:complications / Q000188:drug therapy*; D015996:Survival Rate
D010725:Phosphocreatine; D000804:Angiotensin II; D010656:Phenylephrine; C025403:phosphocreatinine; D000255:Adenosine Triphosphate